Predicine is a molecular insights company that is committed to developing the best-in-class precision diagnostics to address the unmet medical needs worldwide. Predicine's proprietary GeneRADAR technology is the industry's first ctDNA+ctRNA combo liquid biopsy test that provides a comprehensive understanding of the molecular alterations in cancer. Through its CLIA/CAP facilities in US (California) and China (Shanghai, Harbin), Predicine partners with leading biopharma companies and hospitals to support global clinical trials, targeted therapy, and early cancer detection.